NCT06176989 2025-10-20Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting40 enrolled
NCT02273739 2021-02-23Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 MutationCelgenePhase 1/2 Completed21 enrolled 33 charts